Published in Nat Prod Rep on March 01, 2015
Amantelides A and B, Polyhydroxylated Macrolides with Differential Broad-Spectrum Cytotoxicity from a Guamanian Marine Cyanobacterium. J Nat Prod (2015) 0.82
Comparative mass spectrometry-based metabolomics strategies for the investigation of microbial secondary metabolites. Nat Prod Rep (2016) 0.80
Tiny Microbes with a Big Impact: The Role of Cyanobacteria and Their Metabolites in Shaping Our Future. Mar Drugs (2016) 0.75
Hierridin B Isolated from a Marine Cyanobacterium Alters VDAC1, Mitochondrial Activity, and Cell Cycle Genes on HT-29 Colon Adenocarcinoma Cells. Mar Drugs (2016) 0.75
Caldoramide, a Modified Pentapeptide from the Marine Cyanobacterium Caldora penicillata. J Nat Prod (2016) 0.75
Discovery, Total Synthesis and Key Structural Elements for the Immunosuppressive Activity of Cocosolide, a Symmetrical Glycosylated Macrolide Dimer from Marine Cyanobacteria. Chemistry (2016) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
The hallmarks of cancer. Cell (2000) 113.05
Chromatin modifications and their function. Cell (2007) 55.98
Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet (2000) 24.22
Quorum sensing in bacteria. Annu Rev Microbiol (2001) 14.41
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
Microtubules as a target for anticancer drugs. Nat Rev Cancer (2004) 13.93
The druggable genome. Nat Rev Drug Discov (2002) 13.61
A gene expression database for the molecular pharmacology of cancer. Nat Genet (2000) 13.31
Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod (2012) 13.27
The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer (2006) 11.49
Effects of cytochalasin and phalloidin on actin. J Cell Biol (1987) 10.32
Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26
Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A (2001) 7.51
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol (2007) 6.16
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol (2007) 5.17
Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov (2010) 4.66
Structure and biosynthesis of the jamaicamides, new mixed polyketide-peptide neurotoxins from the marine cyanobacterium Lyngbya majuscula. Chem Biol (2004) 4.58
The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer (2007) 4.40
Bioactive natural products from marine cyanobacteria for drug discovery. Phytochemistry (2007) 4.27
Natural combinatorial peptide libraries in cyanobacterial symbionts of marine ascidians. Nat Chem Biol (2006) 4.12
Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure (2004) 3.31
Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov (2006) 3.27
Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci U S A (2004) 3.27
Target profiling of small molecules by chemical proteomics. Nat Chem Biol (2009) 3.20
FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res (2002) 2.90
Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol (1998) 2.78
Quorum sensing inhibitors: an overview. Biotechnol Adv (2012) 2.56
Actin structure and function. Annu Rev Biophys (2011) 2.46
Target identification using drug affinity responsive target stability (DARTS). Proc Natl Acad Sci U S A (2009) 2.40
Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J Am Chem Soc (2008) 2.34
Lessons from the past and charting the future of marine natural products drug discovery and chemical biology. Chem Biol (2012) 2.29
Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol (2012) 2.26
Kinase mutations in human disease: interpreting genotype-phenotype relationships. Nat Rev Genet (2010) 2.14
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol (2012) 2.06
Total structure determination of apratoxin A, a potent novel cytotoxin from the marine cyanobacterium Lyngbya majuscula. J Am Chem Soc (2001) 2.06
From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries. Angew Chem Int Ed Engl (2002) 2.03
Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol (2013) 2.01
Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem (1991) 1.97
Mechanisms and molecular probes of sirtuins. Chem Biol (2008) 1.90
Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev Mol Med (2009) 1.84
FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res (1998) 1.78
Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. J Am Chem Soc (2008) 1.76
Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. J Nat Prod (2001) 1.75
Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res (2000) 1.74
Binding structure of elastase inhibitor scyptolin A. Chem Biol (2003) 1.71
Chemical mechanisms of histone lysine and arginine modifications. Biochim Biophys Acta (2008) 1.69
Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor. J Am Chem Soc (2008) 1.64
Marine natural product aurilide activates the OPA1-mediated apoptosis by binding to prohibitin. Chem Biol (2011) 1.61
COPD: current therapeutic interventions and future approaches. Eur Respir J (2005) 1.61
The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore. J Pharmacol Exp Ther (2002) 1.59
Using transcriptome sequencing to identify mechanisms of drug action and resistance. Nat Chem Biol (2012) 1.53
Lyngbyastatins 5-7, potent elastase inhibitors from Floridian marine cyanobacteria, Lyngbya spp. J Nat Prod (2007) 1.42
Cathepsins and their involvement in immune responses. Swiss Med Wkly (2010) 1.40
Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol (1990) 1.34
Isolation, structure determination, and biological activity of Lyngbyabellin A from the marine cyanobacterium lyngbya majuscula. J Nat Prod (2000) 1.32
Apratoxin D, a potent cytotoxic cyclodepsipeptide from papua new guinea collections of the marine cyanobacteria Lyngbya majuscula and Lyngbya sordida. J Nat Prod (2008) 1.29
Natural products as chemical probes. ACS Chem Biol (2010) 1.29
Apratoxin a reversibly inhibits the secretory pathway by preventing cotranslational translocation. Mol Pharmacol (2009) 1.28
Target identification for small bioactive molecules: finding the needle in the haystack. Angew Chem Int Ed Engl (2013) 1.28
Apratoxin E, a cytotoxic peptolide from a guamanian collection of the marine cyanobacterium Lyngbya bouillonii. J Nat Prod (2008) 1.28
Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases. J Am Chem Soc (2011) 1.26
Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J Org Chem (2003) 1.25
Antimalarial peptides from marine cyanobacteria: isolation and structural elucidation of gallinamide A. J Nat Prod (2009) 1.25
New apratoxins of marine cyanobacterial origin from Guam and Palau. Bioorg Med Chem (2002) 1.24
Evolved diversification of a modular natural product pathway: apratoxins F and G, two cytotoxic cyclic depsipeptides from a Palmyra collection of Lyngbya bouillonii. Chembiochem (2010) 1.22
Antillatoxin is a marine cyanobacterial toxin that potently activates voltage-gated sodium channels. Proc Natl Acad Sci U S A (2001) 1.20
A functional genomics approach to the mode of action of apratoxin A. Nat Chem Biol (2006) 1.20
Structure and absolute stereochemistry of hectochlorin, a potent stimulator of actin assembly. J Nat Prod (2002) 1.19
Chemodiversity in freshwater and terrestrial cyanobacteria - a source for drug discovery. Curr Drug Targets (2011) 1.15
Hoiamide a, a sodium channel activator of unusual architecture from a consortium of two papua new Guinea cyanobacteria. Chem Biol (2009) 1.15
Isolation, structure determination, and biological activity of dolastatin 12 and lyngbyastatin 1 from Lyngbya majuscula/Schizothrix calcicola cyanobacterial assemblages. J Nat Prod (1998) 1.15
Combinatorial strategies by marine cyanobacteria: symplostatin 4, an antimitotic natural dolastatin 10/15 hybrid that synergizes with the coproduced HDAC inhibitor largazole. Chembiochem (2009) 1.14
Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms. Oncogene (2012) 1.14
Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor. J Pharmacol Exp Ther (2010) 1.13
Cytotoxic halogenated macrolides and modified peptides from the apratoxin-producing marine cyanobacterium Lyngbya bouillonii from Guam. J Nat Prod (2010) 1.13
The secret life of kinases: functions beyond catalysis. Cell Commun Signal (2011) 1.13
Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery. Curr Cancer Drug Targets (2009) 1.11
Exploiting genomics, genetics and chemistry to combat antibiotic resistance. Nat Rev Genet (2003) 1.10
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem (2009) 1.09
Cyclodepsipeptide toxin promotes the degradation of Hsp90 client proteins through chaperone-mediated autophagy. J Cell Biol (2009) 1.09
Symplostatin 1: A dolastatin 10 analogue from the marine cyanobacterium Symploca hydnoides. J Nat Prod (1998) 1.07
Synthesis and activity of largazole analogues with linker and macrocycle modification. Org Lett (2008) 1.07
Speciation and biosynthetic variation in four dictyoceratid sponges and their cyanobacterial symbiont, Oscillatoria spongeliae. Chem Biol (2005) 1.06
Total synthesis of the depsipeptide FR-901375. J Org Chem (2003) 1.06
Total structure determination of grassypeptolide, a new marine cyanobacterial cytotoxin. Org Lett (2008) 1.06
Palmyrolide A, an unusually stabilized neuroactive macrolide from Palmyra Atoll cyanobacteria. Org Lett (2010) 1.06
Morphobase, an encyclopedic cell morphology database, and its use for drug target identification. Chem Biol (2012) 1.05
Localization of the antimitotic peptide and depsipeptide binding site on beta-tubulin. Biochemistry (2004) 1.04
Largazole: from discovery to broad-spectrum therapy. Nat Prod Rep (2012) 1.03
Dolastatin 11, a marine depsipeptide, arrests cells at cytokinesis and induces hyperpolymerization of purified actin. Mol Pharmacol (2001) 1.03
Natural products chemistry and taxonomy of the marine cyanobacterium Blennothrix cantharidosmum. J Nat Prod (2008) 1.02
Systematic Chemical Mutagenesis Identifies a Potent Novel Apratoxin A/E Hybrid with Improved in Vivo Antitumor Activity. ACS Med Chem Lett (2011) 1.02
Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer (2003) 1.01
Almiramides A-C: discovery and development of a new class of leishmaniasis lead compounds. J Med Chem (2010) 1.01
Cryptophycin: a new antimicrotubule agent active against drug-resistant cells. Cancer Res (1994) 1.01
Isolation and structure of the cytotoxin lyngbyabellin B and absolute configuration of lyngbyapeptin A from the marine cyanobacterium Lyngbya majuscula. J Nat Prod (2000) 1.00
Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives. Bioorg Med Chem (2008) 0.99
The hoiamides, structurally intriguing neurotoxic lipopeptides from Papua New Guinea marine cyanobacteria. J Nat Prod (2010) 0.99
Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J Am Chem Soc (2008) 2.34
Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. J Am Chem Soc (2008) 1.76
A small-molecule inducer of the antioxidant response element. Chem Biol (2010) 1.65
Marine natural products: a new wave of drugs? Future Med Chem (2011) 1.57
Telomere-independent Rap1 is an IKK adaptor and regulates NF-kappaB-dependent gene expression. Nat Cell Biol (2010) 1.47
A genomic screen for activators of the antioxidant response element. Proc Natl Acad Sci U S A (2007) 1.44
Lyngbyastatins 5-7, potent elastase inhibitors from Floridian marine cyanobacteria, Lyngbya spp. J Nat Prod (2007) 1.42
Lyngbyastatin 4, a dolastatin 13 analogue with elastase and chymotrypsin inhibitory activity from the marine cyanobacterium Lyngbya confervoides. J Nat Prod (2007) 1.32
Apratoxin a reversibly inhibits the secretory pathway by preventing cotranslational translocation. Mol Pharmacol (2009) 1.28
Apratoxin E, a cytotoxic peptolide from a guamanian collection of the marine cyanobacterium Lyngbya bouillonii. J Nat Prod (2008) 1.28
Isolation and biological evaluation of 8-epi-malyngamide C from the Floridian marine cyanobacterium Lyngbya majuscula. J Nat Prod (2010) 1.27
Phylogenetic and chemical diversity of three chemotypes of bloom-forming lyngbya species (Cyanobacteria: Oscillatoriales) from reefs of southeastern Florida. Appl Environ Microbiol (2009) 1.17
Combinatorial strategies by marine cyanobacteria: symplostatin 4, an antimitotic natural dolastatin 10/15 hybrid that synergizes with the coproduced HDAC inhibitor largazole. Chembiochem (2009) 1.14
Cytotoxic halogenated macrolides and modified peptides from the apratoxin-producing marine cyanobacterium Lyngbya bouillonii from Guam. J Nat Prod (2010) 1.13
Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor. J Pharmacol Exp Ther (2010) 1.13
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem (2009) 1.09
Synthesis and activity of largazole analogues with linker and macrocycle modification. Org Lett (2008) 1.07
Total structure determination of grassypeptolide, a new marine cyanobacterial cytotoxin. Org Lett (2008) 1.06
Molassamide, a depsipeptide serine protease inhibitor from the marine cyanobacterium Dichothrix utahensis. J Nat Prod (2010) 1.06
Largazole: from discovery to broad-spectrum therapy. Nat Prod Rep (2012) 1.03
Systematic Chemical Mutagenesis Identifies a Potent Novel Apratoxin A/E Hybrid with Improved in Vivo Antitumor Activity. ACS Med Chem Lett (2011) 1.02
Lyngbyastatins 8-10, elastase inhibitors with cyclic depsipeptide scaffolds isolated from the marine cyanobacterium Lyngbya semiplena. Mar Drugs (2009) 1.01
Lyngbyoic acid, a "tagged" fatty acid from a marine cyanobacterium, disrupts quorum sensing in Pseudomonas aeruginosa. Mol Biosyst (2011) 0.97
Total synthesis and biological evaluation of grassypeptolide A. Chemistry (2013) 0.95
Kempopeptins A and B, serine protease inhibitors with different selectivity profiles from a marine cyanobacterium, Lyngbya sp. J Nat Prod (2008) 0.94
Grassypeptolides A-C, cytotoxic bis-thiazoline containing marine cyclodepsipeptides. J Org Chem (2010) 0.93
Largamides A-C, tiglic acid-containing cyclodepsipeptides with elastase-inhibitory activity from the marine cyanobacterium Lyngbya confervoides. Planta Med (2009) 0.93
The molecular pharmacology of symplostatin 1: a new antimitotic dolastatin 10 analog. Int J Cancer (2003) 0.93
Caylobolide B, a macrolactone from symplostatin 1-producing marine cyanobacteria Phormidium spp. from Florida. J Nat Prod (2010) 0.92
Pitiprolamide, a proline-rich dolastatin 16 analogue from the marine cyanobacterium Lyngbya majuscula from Guam. J Nat Prod (2010) 0.92
Cyanobacterial peptides as a prototype for the design of potent β-secretase inhibitors and the development of selective chemical probes for other aspartic proteases. J Med Chem (2012) 0.92
Seaweed extracts and unsaturated fatty acid constituents from the green alga Ulva lactuca as activators of the cytoprotective Nrf2-ARE pathway. Free Radic Biol Med (2013) 0.91
Protection of human cultured cells against oxidative stress by Rhodiola rosea without activation of antioxidant defenses. Free Radic Biol Med (2009) 0.90
Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells. J Med Chem (2013) 0.89
Tiglicamides A-C, cyclodepsipeptides from the marine cyanobacterium Lyngbya confervoides. Phytochemistry (2009) 0.88
Dragonamides C and D, linear lipopeptides from the marine cyanobacterium brown Lyngbya polychroa. J Nat Prod (2008) 0.88
Caldora penicillata gen. nov., comb. nov. (cyanobacteria), a pantropical marine species with biomedical relevance. J Phycol (2015) 0.88
Discovery and mechanism of natural products as modulators of histone acetylation. Curr Drug Targets (2012) 0.87
Combination therapy for renal cell cancer: what are possible options? Oncology (2011) 0.86
Malyngamide 3 and cocosamides A and B from the marine cyanobacterium Lyngbya majuscula from Cocos Lagoon, Guam. J Nat Prod (2011) 0.85
Veraguamides A-G, cyclic hexadepsipeptides from a dolastatin 16-producing cyanobacterium Symploca cf. hydnoides from Guam. J Nat Prod (2011) 0.85
Pitipeptolides C-F, antimycobacterial cyclodepsipeptides from the marine cyanobacterium Lyngbya majuscula from Guam. Phytochemistry (2011) 0.84
Total synthesis of grassystatin A, a probe for cathepsin E function. Bioorg Med Chem (2012) 0.84
Continuing studies on the cyanobacterium Lyngbya sp.: isolation and structure determination of 15-norlyngbyapeptin A and lyngbyabellin D. J Nat Prod (2003) 0.83
Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma? Oncol Rev (2011) 0.83
Amantelides A and B, Polyhydroxylated Macrolides with Differential Broad-Spectrum Cytotoxicity from a Guamanian Marine Cyanobacterium. J Nat Prod (2015) 0.82
In Vitro and In Vivo Osteogenic Activity of Largazole. ACS Med Chem Lett (2011) 0.82
Activation of the antioxidant response element by specific oxidized metabolites of linoleic acid. Prostaglandins Leukot Essent Fatty Acids (2009) 0.81
Improved total synthesis and biological evaluation of potent apratoxin S4 based anticancer agents with differential stability and further enhanced activity. J Med Chem (2014) 0.80
Weapons in disguise--activating mechanisms and protecting group chemistry in nature. Chemistry (2010) 0.80
Intramolecular modulation of serine protease inhibitor activity in a marine cyanobacterium with antifeedant properties. Mar Drugs (2010) 0.80
Bioassay-guided isolation and identification of desacetylmicrocolin B from Lyngbya cf. polychroa. Planta Med (2009) 0.79
Marine cyanobacterial fatty acid amides acting on cannabinoid receptors. Chembiochem (2012) 0.79
In vitro and in vivo characterization of a tunable dual-reactivity probe of the Nrf2-ARE pathway. ACS Chem Biol (2013) 0.78
Cultivated sea lettuce is a multiorgan protector from oxidative and inflammatory stress by enhancing the endogenous antioxidant defense system. Cancer Prev Res (Phila) (2013) 0.78
Grassypeptolides as natural inhibitors of dipeptidyl peptidase 8 and T-cell activation. Chembiochem (2014) 0.78
Combination therapy targeting cancer metabolism. Med Hypotheses (2010) 0.77
Biological effects of Byrsocarpus coccineus in vitro. Pharm Biol (2010) 0.77
Modular strategies for structure and function employed by marine cyanobacteria: characterization and synthesis of pitinoic acids. Org Lett (2013) 0.77
Caldoramide, a Modified Pentapeptide from the Marine Cyanobacterium Caldora penicillata. J Nat Prod (2016) 0.75
Porpoisamides A and B, two novel epimeric cyclic depsipeptides from a Florida Keys collection of Lyngbya sp. Bioorg Med Chem (2011) 0.75
Construction and characterization of melanocortin-2 and -4 receptor chimeras. Adv Exp Med Biol (2009) 0.75
Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer. J Nat Prod (2017) 0.75
Discovery, Synthesis, and Biological Evaluation of Anaenamides C and D from a New Marine Cyanobacterium, sp. J Nat Prod (2022) 0.75
Correction to Caylobolide B, a Macrolactone from Symplostatin 1-Producing Marine Cyanobacteria Phormidium spp. from Florida. J Nat Prod (2016) 0.75
Apratyramide, a Marine-Derived Peptidic Stimulator of VEGF-A and Other Growth Factors with Potential Application in Wound Healing. ACS Chem Biol (2017) 0.75